We have located links that may give you full text access.
Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
Journal of Nuclear Medicine 1994 December
UNLABELLED: The influence of cumulative absorbed dose, initial dose rate and mass of the remnant thyroid tissue on outcome of radioiodine treatment was assessed to determine an optimum value of absorbed dose and initial dose rate predictive of successful ablation.
METHODS: In 87 patients with thyroid carcinoma treated with 0.85-9.55 GBq (23-258 mCi) of 131I to ablate residual thyroid tissue, the cumulative absorbed dose and the initial dose rate were calculated. Following therapy, the parameters of radioactive iodine uptake and effective half-life were determined in each patient from the surface neck exposure rates measured using a beta/gamma exposure rate meter. Mass of the thyroid remnant was determined from rectilinear images after scatter correction obtained from phantom studies.
RESULTS: Sixty-eight patients showed complete ablation and 19 showed partial ablation of the thyroid remnant after radioiodine therapy. The cumulative absorbed doses delivered to the tissue in completely ablated and partially ablated groups were not significantly different (0.6 > p > 0.5). The initial dose rate delivered to the tissue in both groups, however, showed a significant difference (0.05 > p > 0.02). An initial dose rate of 3 Gy/hr or more completely ablated up to 5 g of tissue in 54 out of 62 patients (87.1%). Dose rate above 3 Gy/hr and cumulative doses above 300 Gy resulted in ablation in 50% of patients with more than 5 g of tissue.
CONCLUSION: In patients receiving 131I to ablate thyroid remnant, the initial dose rate and the tissue mass are determinants of successful treatment response.
METHODS: In 87 patients with thyroid carcinoma treated with 0.85-9.55 GBq (23-258 mCi) of 131I to ablate residual thyroid tissue, the cumulative absorbed dose and the initial dose rate were calculated. Following therapy, the parameters of radioactive iodine uptake and effective half-life were determined in each patient from the surface neck exposure rates measured using a beta/gamma exposure rate meter. Mass of the thyroid remnant was determined from rectilinear images after scatter correction obtained from phantom studies.
RESULTS: Sixty-eight patients showed complete ablation and 19 showed partial ablation of the thyroid remnant after radioiodine therapy. The cumulative absorbed doses delivered to the tissue in completely ablated and partially ablated groups were not significantly different (0.6 > p > 0.5). The initial dose rate delivered to the tissue in both groups, however, showed a significant difference (0.05 > p > 0.02). An initial dose rate of 3 Gy/hr or more completely ablated up to 5 g of tissue in 54 out of 62 patients (87.1%). Dose rate above 3 Gy/hr and cumulative doses above 300 Gy resulted in ablation in 50% of patients with more than 5 g of tissue.
CONCLUSION: In patients receiving 131I to ablate thyroid remnant, the initial dose rate and the tissue mass are determinants of successful treatment response.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app